Paper37569710
A Tailored Approach to Leishmaniases Vaccination: Comparative Evaluation of the Efficacy and Cross-Protection Capacity of DNA vs. Peptide-Based Vaccines in a Murine Model.
Mas A and 6 others. Int J Mol Sci, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. A Tailored Approach to Leishmaniases Vaccination: Comparative Evaluation of the Efficacy and Cross-Protection Capacity of DNA vs. Peptide-Based Vaccines in a Murine Model. Papers, record 37569710. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37569710
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Tailored Approach to Leishmaniases Vaccination: Comparative Evaluation of the Efficacy and Cross-Protection Capacity of DNA vs. Peptide-Based Vaccines in a Murine Model.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Vaccines, DNA | Major topic |
| Leishmaniasis | Major topic |
| Leishmaniasis Vaccines | Major topic |
| Leishmania infantum | Major topic |
| Leishmaniasis, Visceral | Major topic |
| Animals | |
| Mice | |
| Disease Models, Animal | |
| Vaccination | |
| DNA | |
| Mice, Inbred BALB C | |
| Antigens, Protozoan |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PID2019-106487RB-I00/AEI/10.13039/501100011033 | Government of Spain | PubMed | ||
| S2018/BAA-4370 | Comunidad de Madrid | PubMed |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23916336 | Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran. | Pathog Glob Health | 2013 | https://conductscience.org/library/papers/23916336 | PubMed |
| 2 | 33824489 | Emerging concepts in the science of vaccine adjuvants. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33824489 | PubMed |
| 3 | 28915996 | Alternative strategy for visceral leishmaniosis control: HisAK70-Salmonella Choleraesuis-pulsed dendritic cells. | Comp Immunol Microbiol Infect Dis | 2017 | https://conductscience.org/library/papers/28915996 | PubMed |
| 4 | 36365010 | Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. | Pathogens | 2022 | https://conductscience.org/library/papers/36365010 | PubMed |
| 5 | 31635276 | Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments. | Vaccines (Basel) | 2019 | https://conductscience.org/library/papers/31635276 | PubMed |
| 6 | 34428435 | Advancement in leishmaniasis diagnosis and therapeutics: An update. | Eur J Pharmacol | 2021 | https://conductscience.org/library/papers/34428435 | PubMed |
| 7 | 26895806 | Visceral leishmaniasis: a forgotten epidemic. | Arch Dis Child | 2016 | https://conductscience.org/library/papers/26895806 | PubMed |
| 8 | 29163510 | The Equivocal Role of Th17 Cells and Neutrophils on Immunopathogenesis of Leishmaniasis. | Front Immunol | 2017 | https://conductscience.org/library/papers/29163510 | PubMed |
| 9 | 28192528 | CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production. | PLoS Pathog | 2017 | https://conductscience.org/library/papers/28192528 | PubMed |
| 10 | 36336425 | Leishmaniasis. | Vet Clin North Am Small Anim Pract | 2022 | https://conductscience.org/library/papers/36336425 | PubMed |
| 11 | 22693548 | Leishmaniasis worldwide and global estimates of its incidence. | PLoS One | 2012 | https://conductscience.org/library/papers/22693548 | PubMed |
| 12 | 27615509 | Leishmania infantum antigens modulate memory cell subsets of liver resident T lymphocyte. | Immunobiology | 2017 | https://conductscience.org/library/papers/27615509 | PubMed |
| 13 | 27424773 | Cutaneous leishmaniasis: immune responses in protection and pathogenesis. | Nat Rev Immunol | 2016 | https://conductscience.org/library/papers/27424773 | PubMed |
| 14 | 26590047 | Impairment of Interleukin-17A Expression in Canine Visceral Leishmaniosis is Correlated with Reduced Interferon-γ and Inducible Nitric Oxide Synthase Expression. | J Comp Pathol | 2015 | https://conductscience.org/library/papers/26590047 | PubMed |
| 15 | 29441060 | Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. | Front Immunol | 2018 | https://conductscience.org/library/papers/29441060 | PubMed |
| 16 | 31739549 | Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice. | Vaccines (Basel) | 2019 | https://conductscience.org/library/papers/31739549 | PubMed |
| 17 | 31300103 | Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection. | Comp Immunol Microbiol Infect Dis | 2019 | https://conductscience.org/library/papers/31300103 | PubMed |
| 18 | 3598227 | Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. | J Infect Dis | 1987 | https://conductscience.org/library/papers/3598227 | PubMed |
| 19 | 18040886 | L-arginine metabolism and its impact on host immunity against Leishmania infection. | Immunol Res | 2008 | https://conductscience.org/library/papers/18040886 | PubMed |
| 20 | 26937644 | A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. | PLoS Negl Trop Dis | 2016 | https://conductscience.org/library/papers/26937644 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41345965 | Evaluation of the safety and immunogenicity of a peptide vaccine against canine leishmaniosis: a double-blind, multicenter, controlled clinical trial in dogs. | Vet Q | 2025 | https://conductscience.org/library/papers/41345965 | PubMed |
| 41238927 | Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control. | Acta Parasitol | 2025 | https://conductscience.org/library/papers/41238927 | PubMed |
| 41183128 | Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/41183128 | PubMed |
| 38396573 | Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity. | Animals (Basel) | 2024 | https://conductscience.org/library/papers/38396573 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37569710
GET https://conductscience.org/api/papers/v1/37569710/references?page=2